Korea Research Institute of Bioscience and Biotechnology

Dongguk University Industry-academic Cooperation Foundation

St Pharm Co., Ltd.

Immunomet Therapeutics Inc.

Kyung-Sook Chung

Young Ho Kim

Young Il Yeom

Hee Gu Lee

Eun Young Song

Kyeong Seok Lee

Moon Hee Kim

Kyeong-Eun Jung

Kyung Bin Song

Misun Won

Chae Ok Yun

Mi Sun Won

Young Joo Kim

Yu-Kyoung Oh

Hwan-Mook Kim

Ki-ho Lee

Song-Kyu Park

Chang-Woo Lee

Seon-Young Kim

Ho Kyung Chun

Hyun-Seung Ban

Bo-Kyung Kim

Naik Ravi

Hye Kyung Hong

Mi-Sun Won

Sung Wuk Kim

Jae Wha Kim

Chae-Ok Yun

Hong Bum Lee

Young-Joo Kim

Myung Jin Son

Hyun Seung Ban

Min Ah Kang

Jae Sung Ryu

Seonju Mun

Jiae Kook

Sanghee Yoo

Jiwon Ahn

Youjeong Kwon

Hyang Sin Lee

In Seong Choe

Mi Young Park

Sun-Jung Cho

Shin-Jung Choi

Seohyun Son

The present invention relates to a composition for hair improvement, and more specifically to a composition for promoting hair growth, or preventing or treating hair loss, comprising a guanine derivative having no toxicity as an active ingredient. The composition has excellent effects of promoting hair growth and regenerating hair follicles, and thus can be effectively used in various fields such as pharmaceutical, food, feed, and cosmetic compositions for promoting hair growth, or preventing, treating, and improving hair loss.

Composition for promoting hair growth comprising a guanine derivative

The present invention relates to novel compounds as HIF-1&#x3b1; inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1&#x3b1;, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1&#x3b1;-mediated VEGFA expression.

Compounds as HIF-1&#x3b1; inhibitors and manufacturing process thereof

The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1&#x3b1;, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, &#x3b2;-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.

Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient

Compounds as HIF-1alphainhibitors and manufacturing process thereof

The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.

Pharmaceutical composition for treating cancer

Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.

Use of FLJ25416 gene

Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Characterization of ESM-1 as a tumor associated marker of colorectal cancer

Growing community of inventors

Daejeon, South Korea

Kyung-Sook Chung